



ASX / Media Release
18 June 2024

Non-Executive Director Resignation

Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company) a biopharmaceutical company focused on the development and commercialisation of Exenatide for neurological conditions relating to raised intracranial pressure, announces that Dr. Megan Baldwin has advised of her decision to retire as a Non-executive director of the Company effective 30 June 2024.

Invex Chair Mr. David McAuliffe commented “I wish to sincerely thank Dr. Baldwin for her service to Invex where she has served as a Non-executive director since February 2021. Dr. Baldwin has been a strong and significant contributor to the Board, joining the Company at a critical point as we advanced Exenatide from Phase II to Phase III clinical trials in IHH. , we thank Dr. Baldwin for her contributions to the Company and wish her all the best for future endeavours.”

- ENDS -

This release dated 18 June 2024 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics.

For more information, please contact:

Company/Investors

Dr Thomas Duthy
Executive Director
tduthy@invextherapeutics.com
+61 402 493 727

Media

Margie Livingston
Ignite Communications
margie@ignitecommunications.com.au
+61 438 661 131

To subscribe to Invex email alerts, please visit www.invextherapeutics.com and follow us on Twitter [@InvexThera_ASX](https://twitter.com/InvexThera_ASX)

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.

